From successful launch, to accelerating toward the next frontier

We are immensely proud of the robust portfolio of products with life-saving potential that we have created with our ever-expanding network of partners in Japan and around the world during our first five years. As a result of this work, the global health R&D pipeline is more vibrant than ever, leveraging Japanese innovation to help realize the promise of better, more prosperous lives for hundreds of millions of people across the globe.

This work moves the world closer toward our shared universal health coverage, Sustainable Development, and human security goals. Following our launch five years ago, we are honored that...
We are immensely proud of the robust portfolio of products with life-saving potential that we have created with our ever-expanding network of partners in Japan and around the world during our first five years. As a result of this work, the global health R&D pipeline is more vibrant than ever, leveraging Japanese innovation to help realize the promise of better, more prosperous lives for hundreds of millions of people across the globe.

This work moves the world closer toward our shared universal health coverage, Sustainable Development, and human security goals. Following our launch five years ago, we are honored that new investment platforms like Coalition for Epidemic Preparedness Innovations (CEPI) and Research Investment in Global Health Technology (RIGHT) have leveraged GHIT’s pioneering public-private partnership fund model. And thanks to our replenishment for GHIT’s second five-year phase, our capacity to realize the promise of product development is greater than ever.

These achievements illustrate that our business model and role as catalyst and investor in product development are working. But the true measure of success is putting effective, affordable, lifesaving tools into the hands of every person who needs them.

Thanks to the foresight, engagement, creativity, and unwavering support of our funders, sponsors, development partners, and governors, we close our first phase of operations and enter the next with unparalleled energy, optimism, and drive.

The really important work starts now, and we’re ready for it.

BT Slingsby, MD, PhD, MPH
Chief Executive Officer

Kiyoshi Kurokawa, MD
Board Chair

Kiyoshi Kurokawa, MD
Board Chair

BT Slingsby, MD, PhD, MPH
Chief Executive Officer
Advancing Portfolio

Discovery

Target Research Platform

- Malaria
  - Vaccine
  - Diagnostic

Screening Platform

- Tuberculosis
  - Drug
  - Vaccine

NDTs

- Chagas disease, Leishmaniasis
  - Drug

- Chagas disease
  - Drug

- Leishmaniasis
  - Drug

- Schistosomiasis
  - Diagnostic

Hit-to-Lead Platform

- Vaccine
- Vaccine

USD 190M

Co-investment
GHIT Investment

2013 2014 2015 2016 2017

12.8 29.7 32.4 51.1 56.8
18.9 46.0 63.7 98.6 131.9

US dollar amounts represent conversions from Japanese yen, solely for the reader’s convenience, at JPY 100 = USD 1.
As of March 2018
Late-Stage Candidates

**SJ733**
Disease: Malaria  
Intervention: Drug  
Development Stage: Phase IIa  
Country: To be determined  
SJ733 is a chemically novel and potent antimalarial candidate, based on a dihydroisoquinolone platform and featuring good oral availability, excellent safety tolerability, and a low propensity for resistance. The trial will test SJ733 in combination therapy.

**DK-SE36/CpG**
Disease: Malaria  
Intervention: Vaccine  
Development Stage: Phase Ib  
Country: Burkina Faso  
This trial will assess the safety and reactogenicity of three doses of malaria vaccine candidate BK-SE36, formulated with TLR9 ligand adjuvants K3 CpG oligodeoxyribonucleotides (K3 CpG-ODN) in healthy African adults and children exposed to the *Plasmodium falciparum* parasite.

**DSM265**
Disease: Malaria  
Intervention: Drug  
Development Stage: Phase IIb  
Country: To be determined  
DSM 265 is a novel antimalarial candidate anticipated to become a single exposure radical cure and prophylaxis (SERCaP) product. The trial aims to optimize oral formulation and lower the administration volume for pediatric use.

**E1224**
Disease: Chagas disease  
Intervention: Drug  
Development Stage: Phase IIb  
Country: Bolivia  
The trial compares the safety and efficacy of oral E1224 (a water-soluble ravuconazole prodrug) regimens with benznidazole in adults with chronic, indeterminate Chagas disease. The novel candidate treatment regimen is oral, easy to use, safe, and affordable.
**E1224**
Disease: Mycetoma
Intervention: Drug
Development Stage: Phase IIb
Country: Sudan

This trial tests whether Fosravuconazole, an azole-class antifungal drug discovered by Eisai, may also be an effective and affordable treatment for mycetoma. The trial is being conducted with the WHO Collaborating Center on Mycetoma in Khartoum.

**DAR-901**
Disease: Tuberculosis
Intervention: Vaccine
Development Stage: Phase IIb
Country: Tanzania

DAR-901 is the only novel TB booster vaccine candidate based on inactivated whole cell derived from Mycobacterium obuense that has shown efficacy in humans.

**PZQ**
Disease: Schistosomiasis
Intervention: Pediatric Drug
Development Stage (Country):
Phase IIb (Ivory Coast) / Phase III (Kenya)

The Pediatric Praziquantel Consortium developed the pediatric formulation of the gold-standard drug for schistosomiasis to address the unmet medical needs of infected preschool-age children. The formulation under investigation is smaller, exhibits an improved palatability, and is orally dispersible, in contrast to the current commercial formulation.

**TB-LAM**
Disease: Tuberculosis
Intervention: Diagnostic
Development Stage: Product validation
Country: South Africa

This project aims to develop a highly sensitive, rapid point-of-care TB test to diagnose the disease from urine in high-risk, HIV-infected individuals. Product validation studies based on samples from South African townships are under way.
GHIT’s inaugural R&D Forum convened more than 80 Japanese and non-Japanese life science companies, research institutions, universities, international organizations, and nonprofit and nongovernmental organizations to engage in unprecedented, interactive peer-to-peer exchange. Discussions covered R&D project progress, lessons learned, shared challenges and opportunities, and next steps from target research to clinical trials. Participants also shared strategies for identifying appropriate partners for product development, the secrets of successful partnerships, clinical trial challenges in low- and middle-income countries, and effective funder-to-funder collaboration.

Why were these discussions unprecedented? Before GHIT’s founding in 2013, the number of Japanese institutions engaged in global health R&D was small, and few opportunities existed domestically for collaboration and information exchange between Japanese and foreign global health R&D organizations. Fast-forward five years: more than 40 Japanese organizations have participated in GHIT’s investment platforms in partnership with global entities, and GHIT’s development partners continue to expand and accelerate their activities across the globe.
By effectively linking the value chain from fundraising, investment, product development, and delivery, GHIT has created a vibrant, connected, and internationally recognized Japanese global health R&D ecosystem. GHIT’s commitment to accelerating the critical work of this dynamic community remains steadfast, fueling global efforts and harness Japan’s previously untapped science and pharmaceutical capabilities to revolutionize global health.

Japan, as the world’s No.3 leader in pharmaceutical development, offers invaluable technologies, expertise, and know-how for global health R&D. Such assets are now directly linked to overseas product development partners through GHIT, and open innovation continues to create new value and impact.

GHIT is not simply an institution; it works as a global hub for Japanese and overseas institutions from all sectors involved in global health R&D, and facilitates international collaboration, open innovation, and outcome-oriented dialogue on product development, access, and delivery.
Moderator Reflections

Kei Katsuno, MD, MPH
Senior Director, Investment Strategy & Government Relations
GHIT Fund

The engagement of Japanese organizations in global health R&D has expanded dramatically over the past five years. I realized that scientists across the world share unwavering commitment and passion, a key powering force driving global health R&D. I hope that opportunities like the R&D Forum will contribute to building new partnerships in Japan and overseas, as well as encourage deeper discussion among partners.

Hayato Urabe, PhD, MPIA
Director, Investment Strategy, Planning & Management
GHIT Fund

The R&D Forum catalyzed lively discussions beyond immediate projects and R&D stages of focus -- more so than we had imagined it would. This was incredibly gratifying for all of us at GHIT. I believe that proactive partnerships between Japan and overseas entities not only allow us to position GHIT's work within the global portfolio but also create great impact in terms of fundraising, investment, and access.

Participating Organizations

Ahmada Bello University (ABU Zaria)
Astellas Pharma Inc.
Australian Department of Foreign Affairs and Trade
Bayer
Bill & Melinda Gates Foundation
CellFree Sciences Co., Ltd.
Chiba-Nishi General Hospital
ChemRoutes Corporation
Chugai Pharmaceutical Co., Ltd.
Daichi Sankyo Co., Ltd.
Daichi Sankyo RD Novare Co., Ltd.
Daiken Medical Co. Ltd.
Drugs for Neglected Diseases initiative (DNDi)
Drugs for Neglected Diseases initiative Japan (DNDi Japan)
Ehime University
Eisai Co., Ltd.
Eisai Inc.
Embassy of Canada to Japan
EU-Japan Centre for Industrial Cooperation
European & Developing Countries Clinical Trials Partnership (EDCTP)
European Vaccine Initiative (EVI)
Fujifilm Corporation
Global Alliance for TB Drug Development (TB Alliance)
GSK Japan
HanaVax Inc
Health and Global Policy Institute
Hindu University
Inc., Ohio
Geisel School of Medicine at Dartmouth
Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine
International AIDS Vaccine Initiative (IAVI)
International Vaccine Institute (IVI)
Janssen Pharmaceutical K.K.
Japan Agency for Medical Research and Development (AMED)
Japan Anti-Tuberculosis Association, Research Institute of Tuberculosis
Japan Innovation Network
Johnson & Johnson
Jublant Biosys Ltd.
Keio University School of Medicine
Kitasato Daichi Sankyo Vaccine Co., Ltd.
Kitasato University School of Medicine
Kyoto University
Lygature
Malaria No More Japan
Medicines for Malaria Venture (MMV)
Medicines Patent Pool
Meiji Seika Pharma Co., Ltd.
Ministry of Foreign Affairs of Japan
Ministry of Health, Labour and Welfare of Japan
Mitsubishi Tanabe Pharma Corporation
Nagoya University
National Center for Global Health and Medicine (NCGM)
National Institute of Infectious Diseases
National University of Singapore
Nobelpharma Co., Ltd
Non-Profit Organization Center for Application of Chemical Compounds
Obihiro University of Agriculture and Veterinary Medicine
Osaka City University
Osaka University
Otsuka Pharmaceutical Co., Ltd.
PATH
Pfizer Japan
Pharma-Assist
Monash University
RIKEN Center for Life Science Technologies (CLST)
Shionogi & Co., Ltd.
Sophia University
St. Luke's Graduate School of Public Health
St. Luke's International University
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Technology Cross Point Laboratory
Institute of Medical Science, The University of Tokyo
Tokyo Institute of Technology
Tokyo Medical and Dental University
Tokyo Metropolitan Institute of Medical Science
Toyama Chemical Co., Ltd.
Tufts Medical Center
United Nations Development Programme (UNDP)
Unilad
University of Namibia
VLP Therapeutics
Wellcome Trust
World Intellectual Property Organization (WIPO)
Participant Reflections

“The R&D Forum provided useful and interesting glimpses into how other donors and product development partners are working with the GHIT Fund.”

“We felt a strong sense of mission and were inspired by the passion of researchers we met at the R&D Forum to contribute more. I am proud that my company partners with GHIT.”

“The R&D Forum facilitated excellent face-to-face communication with colleagues with whom I normally interact only via e-mail and teleconference. It made all the difference.”

“Valuable experience for young academic researchers/students in the field. They should be made aware of this kind of event. They are the future of this field, R&D and Japanese innovation.”

“The Forum showed how the mindset of Japanese researchers is rapidly shifting from a domestic to a global viewpoint.”

“Great to hear how projects are advancing and learn why partnerships are important.”

“Unique event that enabled Japanese innovation and know-how to shine in a way that is comfortable for Japanese researchers.”

“All of you is GHIT — all of you: scientists and researchers from academia and industry coming together to develop new medicines for patients in low and middle income countries using Japanese innovation. This was the vision when launching GHIT; this is GHIT.”

BT Slingsby, MD, PhD, MPH
GHIT Fund CEO
GHIT Replenishment
June 1, 2017

Clockwise from upper left: Yoshihiko Hatanaka (Representative Director, President and CEO, Astellas Pharma Inc.), Tatsuro Kosaka (President & COO, Chugai Pharmaceutical Co., Ltd.), George Nakayama (Representative Director, Chairman and CEO, Daiichi Sankyo Company, Limited), Haruo Naito (Representative Corporate Officer and CEO, Eisai Co., Ltd.), Isao Teshirogi (President and CEO, Shionogi & Co., Ltd.), Christophe Weber (Representative Director, President and CEO, Takeda Pharmaceutical Company Limited), Stephen Caddick (Director, Innovations Division, Wellcome Trust), Eiji Hinoshita (Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs), Kiyoshi Kurokawa (Representative Director and Chair, GHIT Fund), BT Slingsby (CEO, GHIT Fund), Naoko Yamamoto (Assistant Minister for Global Health, Minister’s Secretariat, Ministry of Health, Labour and Welfare), Andrin Oswald (Director, Life Sciences Partnerships, Bill & Melinda Gates Foundation) *Titles and affiliations at time of press conference.

Funding Partners and Sponsors for GHIT 2.0 (FY2018-FY2022)
On June 1, 2017, GHIT announced its replenishment with a USD 200 million commitment for our next five years (FY2018–FY2022) from its funding partners. In a press conference, Council members, together with GHIT’s Chairman and GHIT’s CEO, reflected on the Fund’s inception, when the Japanese government, Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation collaborated to launch a matching fund to promote product development for infectious diseases by harnessing Japan’s untapped pharmaceutical and technological capabilities. GHIT’s leaders shared examples of key activities and investments that illustrated how, in just five years, Japan’s innovations have made a critical impact on global health R&D.

Replenishment funds enable GHIT to move our most advanced tools out of the lab, and into the hands of those who need them most. Expanded investment capacity will be used to accelerate GHIT’s clinical trials in the developing world, as well as advancing other product development activities to move products to market.

Dr. Isao Teshirogi, President and CEO of Shionogi & Co., Ltd., said “I do not know of any other public-private partnership like [GHIT’s] successful case. It is very rare for CEOs of pharmaceutical companies to get together, but all CEOs here have been strongly committed to and passionate about the GHIT Fund for a long time and for a specific mission." He went on to describe the solidarity and unity between the GHIT Fund and its stakeholders and expressed hope for further changes in attitudes towards global health R&D, including among the Japanese government, companies, and academia. Dr. Teshirogi concluded by noting that “Continuing this momentum reinforces Japan’s leadership and international presence.”

“This public-private partnership matters, because we can maximize and leverage our resources and networks for product development and delivery for patients.”

Stephen Caddick, PhD
Innovation Director
Wellcome Trust
R&D: Investments in Product Development

Further leverage innovations from Japanese biopharma and academia

Five innovative diagnostic technologies identified and funded (Target Research Platform & Product Development Platform)

- 5 Leads
- 5 Hit-to-lead programs
- 8 Candidates
- Eight preclinical candidates identified

Excellence through Good Governance

Ensure and further enhance corporate governance and institutional development
- Two successful audits by the Cabinet Office of Japan (conducted every three years)
- Five successful financial audits by an external and independent auditor
- Five successful internal audits by the GHIT management team (results reported to Chief Executive Officer & Board of Directors)
- Biennial review and sign-off by Board of Directors of updated GHIT policies, including Governance Manual

Financial Strategies

Maximize efficiencies in fund management and co-funding strategies
- Maintain overhead cost (at or below 5%)
- Maintain uniquely low overhead cost in order to maximize investments in R&D
- Increase leveraging factor (to 2.0)
  Leveraging factor = (GHIT’s investment + co-investment by other organizations) / (GHIT’s investment) = 1.5 as of December, 2017

Develop and execute a replenishment plan for GHIT 3.0
- Successfully replenish GHIT 3.0 (FY2023 - FY2027)
- Ensure sustainable operations of GHIT and continued acceleration of product development
GHIT’s Strategic Plan for its second five-years is composed of four pillars: R&D, Partnership for Delivery, Excellence Through Good Governance, and Financial Strategies. By prioritizing investment in late-stage candidates in the pipeline, GHIT will aim to have two products approved by a stringent regulatory authority by the end of FY2022.

**Advance R&D investment pipeline and prioritize late-stage candidates**

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase IIa</th>
<th>Phase IIb</th>
<th>Phase III</th>
<th>Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 FIH</td>
<td>3 POC</td>
<td></td>
<td>2 Products</td>
<td></td>
</tr>
</tbody>
</table>

Five First in Human (FIH) clinical trials conducted. Three clinical candidates with Proof of Concept (POC) achieved. Two products approved by a stringent regulatory authority.

**Refine strategies to maximize global health R&D excellence and outcomes**

- Six preclinical investments and four clinical investments reviewed for effectiveness in the field
- Annual portfolio review approved by the Portfolio and Launch Strategy Committee (PLSC), a standing committee of the GHIT Board of Directors

**Partnership for Delivery**

Strengthen capacity to appraise access and delivery strategies for late-stage candidates

- 10 access and delivery strategies for late-stage investments reviewed by PLSC and reported to the Board of Directors

Leverage United Nations Development Programme (UNDP) and other global network partners for product delivery preparedness

- Six access and delivery strategies shared and discussed with UNDP and other global partners
- Six meetings convened between development partners and relevant global partners for each of the access and delivery strategies aforementioned with the goal of in-country access and delivery support
- Present GHIT’s access and delivery strategies at more than 20 conferences or events

**Accelerating Co-investment**

GHIT and the European & Developing Countries Clinical Trials Partnership (EDCTP) announced a new co-investment partnership on December 8th, 2017 to support the Phase III clinical trial for the pediatric formulation of Praziquantel by the Pediatric Praziquantel Consortium. This funding collaboration amplifies the impact of each organization’s investment exponentially.

Disclaimer: This Strategic Plan contains forward-looking statements and actual results may be materially different from those expected in the forward-looking statements due to a number of risks and uncertainties, including, but not limited to, whether we can sustain funding, achieve successful progression of products through the R&D process, and receive regulatory approvals.
Independent Auditor’s Report

To the Board of Directors, Global Health Innovative Technology Fund:

We have audited the accompanying financial statements, which comprise the balance sheet, the statement of income, the notes to the financial statements, and the related supplementary schedules of the Public Interest Incorporated Association (Global Health Innovative Technology Fund) applicable to the sixth fiscal year ended March 31, 2018. We conducted our audit in accordance with the rules and regulations concerning the Act on the Authorization, etc. of Public Interest Incorporated Associations and Public Interest Incorporated Foundations in Japan, under Article 23.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements and the related supplementary schedules based on our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and the related supplementary schedules are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements and the related supplementary schedules. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements and the related supplementary schedules, whether due to fraud or error. The purpose of an audit of the financial statements is not to express an opinion on the effectiveness of the Organization’s internal control, but in meeting our audit objectives, we consider internal control relevant to the preparation and fair presentation of the financial statements.
# 2017 Financial Summary (Audited)

## ASSETS, LIABILITIES, AND NET ASSETS

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>Millions of Yen</th>
<th>Millions of U.S. Dollars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>¥665.1</td>
<td>$6.3</td>
</tr>
<tr>
<td>Fixed Assets</td>
<td>2,361.8</td>
<td>22.2</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>¥3,026.9</td>
<td><strong>$28.5</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th>Millions of Yen</th>
<th>Millions of U.S. Dollars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Liabilities</td>
<td>¥753.4</td>
<td>$7.1</td>
</tr>
<tr>
<td>Net Assets</td>
<td>2,273.5</td>
<td>21.4</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>¥3,026.9</td>
<td><strong>$28.5</strong></td>
</tr>
</tbody>
</table>

## FUNDS RECEIVED

<table>
<thead>
<tr>
<th>FUNDS RECEIVED</th>
<th>Millions of Yen</th>
<th>Millions of U.S. Dollars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governments, NGOs,</td>
<td>¥1,792.0</td>
<td>$16.9</td>
</tr>
<tr>
<td>Multilateral Organizations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundations</td>
<td>916.8</td>
<td>8.6</td>
</tr>
<tr>
<td>Corporations</td>
<td>1,445.2</td>
<td>13.6</td>
</tr>
<tr>
<td><strong>TOTAL FUNDS RECEIVED</strong></td>
<td>¥4,154.0</td>
<td><strong>$39.1</strong></td>
</tr>
</tbody>
</table>

### SOURCES OF ALLOCATED REVENUE

- **44.2%** Governments, NGOs, Multilateral Organizations
- **37.6%** Foundations
- **18.2%** Corporations

### EXPENSE ALLOCATION

- **95.6%** Program Services
- **4.4%** Support Services

---

*The US dollar amounts in this section represent translations of Japanese yen, solely for the reader’s convenience, at JPY 106.25= USD 1, the approximate exchange rate on March 31, 2018.*

*This financial summary is an excerpt from the GHIT Fund’s audited financial statements, which are audited by Ernst & Young ShinNihon LLC. The GHIT Fund is a Public Interest Incorporated Association and is registered in Japan.*
LEADERSHIP

Our governance structure is designed to structurally transcend potential conflicts of interest that can arise when a company may be both a benefactor and a beneficiary of the Fund. The reason for this is simple: national institutes and universities are critical research partners, but we need companies to champion the development and delivery of products to patients. Companies commit non-dilutive capital to the GHIT Fund but then relinquish all investment and portfolio decision-making to a Board and Management Team that excludes representation from any funding company.

COUNCIL

The Council consists of the Japanese government, various foundations, and private companies that provide funding to GHIT. The Council resolves important matters as provided by applicable laws and regulations or the Articles of Incorporation including appointment and dismissal of members of the Council and the Board of Directors, amendment of the Articles of Incorporation, and approval of financial statements.

BOARD OF DIRECTORS

The Board of Directors consists of global health experts and management professionals. In addition to overseeing operations by the Management Team, it also resolves important business matters including approval of major rules, strategic plans, annual operational plans/budget, and funding decisions based on recommendations from the Selection Committee.
The Selection Committee consists of domestic and international experts who have extensive knowledge and experience in research and development of drugs, vaccines and diagnostics. This committee evaluates investment proposals and reports from development partners and recommends the investments to the Board of Directors. This committee includes no private company representatives to avoid any Conflicts of Interest between our backers and development partners.

Members provide strategic advice to the Board of Directors and to the Management Team.

Management Team Leadership is responsible for the design and development of business and investment strategies and, upon Board approval, the execution of strategies, administrative operations, and organizational growth of GHIT.

As of March 31, 2018
The work of the GHIT community could not progress without vital support from these experts and their institutions.

Richard Adegbola
Yukihiro Akeda
Pedro Alonso
Peter Andersen
Rip Ballou
Lewellys Barker
Michael Barrett
Clif Barry
David Bell
Marleen Boelaert
Maria Elena Bottazzi
Walt Brandt
Tom Brewer
David Brown
Martin Brusdeilins
Nick Cammack
Simon Campbell
Eric Chatelain
Philip Cole
Stewart Cole
Simon Croft
Roy Curtiss
Peter Dailey
Christine Debouck
Thierry Diagana
Thomas Dick
Carter Diggs
Boro Dropulic
Filip Dubovsky
David Edwards
Sabine Ehrt
Hiroyoshi Endo
Joel Ernst
Alan Fairlamb
Hermann Feldmeier
David Fidock
JoAnne Flynn
Michael Free
Takashi Fujitsu
Tamio Fujiwara
Nisha Garg
Ricardo Gazzinelli
Ann Ginsberg
Daniel Goldberg
Glenda Gray
Brian Greenwood
Sanjay Gurunathan
R. Kiplin Guy
Lee Hall
Yoshihisa Hashiguchi
Thomas Hawn
Chris Hentschel
D. Gray Heppner
Philip Hill
Toshihiro Horii
Sanjay Jain
Stephen Johnston
Takushi Kaneko
Niranjan Kanesa-thasan
Shigeyuki Kano
Subhash Kapre
Paul Kaye
Naoto Keicho
David Kelso
Kent Kester
Akinori Kimura
Sue Kinn
Harjeshwar Kohli
Somei Kojima
Hidehito Kotani
Peter Kremsner
Sanjeev Krishna
Michael Kurilla
Dennis Kyle
Nancy Le Cam Bouveret
James LeDuc
Carole Long
Timothy Lu
John Mansfield
Greg Mattashefski
James McCarthy
Joseph McCune
James McKerrow
Carl Mendel
Charles Mgone
Gerd Michel
Toshiyuki Miura
Valerie Mizrahi
Melinda Moree
Kouichi Morita
Charles Mowbray
Peter Myler
Daniel Neafsey
Christian Ockenhouse
Giuseppe Pantaleo
David Persing
Meg Phillips
Punnee Pitisuttithum
David Pompliano
Dominic Pucci
Regina Rabinovich
Rino Rappuoli
Zarifah Reed
Rebecca Richards-Kortum
Paul Roepe
Polly Roy
Eric Rubin
Peter Ruminski
Philip Russell
David Sacks
Judy Sakanari
Dirk Schnappinger
Ami Shah Brown
George Siber
KJ Singh
Peter Smith
David Soane
Lynn Soong
Gerald Spahth
Dan Stinchcomb
Nathalie Strub-Wourgaft
Yasuhiro Suzuki
Marcel Tanner
John Telford
Kaoru Terashima
Katsushi Tokunaga
Nadia Tornieporth
Bruno Travi
Takafumi Tsuboi
Moriya Tsuji
Mickey Urdea
Stephen Ward
Tim Wells
Bruce Weniger
George Whitesides
Samuel Wickline
Judith Wilber
Dyann Wirth
Michael Witty
Paul Wyatt
Kazuhisa Yoshimura
Takeshi Yura
Fidel Zavala
Donato Zipeto
FUNDING PARTNERS & SPONSORS

Full Partners

Associate Partners

Affiliate Partners

Sponsors
The really important work starts now, and we’re ready for it.